Oncogenic potential of BRAF versus RAS

Cancer Letters

Volumn 261, Issue 2, 2008, Pages 137-146

  Benjamin, Cara L ^a   Ananthaswamy, Honnavara N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BRAF; p53; RAS

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; RAS PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CODON; CONTROLLED STUDY; EMBRYO; FEMALE; FIBROBLAST; GENE MUTATION; GENETIC TRANSFECTION; MORPHOLOGY; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE H RAS; ONCOGENE N RAS; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; FEMALE; FIBROBLASTS; GENES, P53; GENES, RAS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; MUTATION; NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS B-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION;

EID: 39149102128     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.10.033     Document Type: Article

References (30)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
2. Dhillon A.S., Hagan S., Rath O., and Kolch W. MAP kinase signalling pathways in cancer. Oncogene 26 (2007) 3279-3290
3. Chin L., Garraway L.A., and Fisher D.E. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 20 (2006) 2149-2182
4. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3 (2003) 11-22
5. Beeram M., Patnaik A., and Rowinsky E.K. Regulation of c-Raf-1: therapeutic implications. Clin. Adv. Hematol. Oncol. 1 (2003) 476-481
6. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
7. Pollock P.M., and Meltzer P.S. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2 (2002) 5-7
8. Maldonado J.L., Fridlyand J., Patel H., Jain A.N., Busam K., Kageshita T., Ono T., Albertson D.G., Pinkel D., and Bastian B.C. Determinants of BRAF mutations in primary melanomas. J. Natl. Cancer Inst. 95 (2003) 1878-1890
9. Nagasaka T., Sasamoto H., Notohara K., Cullings H.M., Takeda M., Kimura K., Kambara T., MacPhee D.G., Young J., Leggett B.A., Jass J.R., Tanaka N., and Matsubara N. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J. Clin. Oncol. 22 (2004) 4584-4594
10. Rushworth L.K., Hindley A.D., O'Neill E., and Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell Biol. 26 (2006) 2262-2272
11. Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., Cruz M.S., McCormick F., and Rauen K.A. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311 (2006) 1287-1290
12. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J., Salem G., Pohida T., Heenan P., Duray P., Kallioniemi O., Hayward N.K., Trent J.M., and Meltzer P.S. High frequency of BRAF mutations in nevi. Nat. Genet. 33 (2003) 19-20
13. Yeung K., Seitz T., Li S., Janosch P., McFerran B., Kaiser C., Fee F., Katsanakis K.D., Rose D.W., Mischak H., Sedivy J.M., and Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401 (1999) 173-177
14. Schuierer M.M., Bataille F., Hagan S., Kolch W., and Bosserhoff A.K. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res. 64 (2004) 5186-5192
15. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., and Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436 (2005) 720-724
16. Garnett M.J., and Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6 (2004) 313-319
17. Sensi M., Nicolini G., Petti C., Bersani I., Lozupone F., Molla A., Vegetti C., Nonaka D., Mortarini R., Parmiani G., Fais S., and Anichini A. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25 (2006) 3357-3364
18. Edlundh-Rose E., Egyhazi S., Omholt K., Mansson-Brahme E., Platz A., Hansson J., and Lundeberg J. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 16 (2006) 471-478
19. Petti C., Molla A., Vegetti C., Ferrone S., Anichini A., and Sensi M. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res. 66 (2006) 6503-6511
20. Lang G.A., Iwakuma T., Suh Y.-A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., El-Naggar A.K., and Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni Syndrome. Cell 119 (2004) 861-872
21. Liu G., Parant J.M., Lang G., Chau P., Chavez-Reyes A., El-Naggar A.K., Multani A., Chang S., and Lozano G. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat. Genet. 36 (2004) 63-68
22. Wellbrock C., Ogilvie L., Hedley D., Karasarides M., Martin J., Niculescu-Duvaz D., Springer C.J., and Marais R. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64 (2004) 2338-2342
23. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery Jr. C.A., Butel J.S., and Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 (1992) 215-221
24. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., and Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4 (1994) 1-7
25. Hinds P., Finlay C., and Levine A.J. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol. 63 (1989) 739-746
26. Chudnovsky Y., Adams A.E., Robbins P.B., Lin Q., and Khavari P.A. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat. Genet. 37 (2005) 745-749
27. Dumaz N., Hayward R., Martin J., Ogilvie L., Hedley D., Curtin J.A., Bastian B.C., Springer C., and Marais R. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 66 (2006) 9483-9491
28. Marais R., Light Y., Paterson H.F., Mason C.S., and Marshall C.J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J. Biol. Chem. 272 (1997) 4378-4783
29. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Shirasawa S., Sasazuki T., and Kerbel R.S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55 (1995) 4575-4580
30. Sharma A., Trivedi N.R., Zimmerman M.A., Tuveson D.A., Smith C.D., and Robertson G.P. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65 (2005) 2412-2421